SG11201408340SA - Angiopoietin-like 4 antibody and a method of its use in cancer treatment - Google Patents

Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Info

Publication number
SG11201408340SA
SG11201408340SA SG11201408340SA SG11201408340SA SG11201408340SA SG 11201408340S A SG11201408340S A SG 11201408340SA SG 11201408340S A SG11201408340S A SG 11201408340SA SG 11201408340S A SG11201408340S A SG 11201408340SA SG 11201408340S A SG11201408340S A SG 11201408340SA
Authority
SG
Singapore
Prior art keywords
nanyang
tct
singapore
cag
ggg
Prior art date
Application number
SG11201408340SA
Inventor
Julien Lescar
Yee Hwa Wong
Wei Min Edmond Chua
Nguan Soon Andrew Tan
Han Chung Kelvin Chong
Ming Jie Tan
Royston-Luke Huang
Original Assignee
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech filed Critical Univ Nanyang Tech
Publication of SG11201408340SA publication Critical patent/SG11201408340SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 February 2014 (20.02.2014) WIPOIPCT (10) International Publication Number WO 2014/027959 A1 (51) International Patent Classification: C07K16/18 (2006.01) A61P 35/04 (2006.01) A61K39/395 (2006.01) (21) International Application Number: (72) (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/SG2013/000331 6 August 2013 (06.08.2013) English English (30) Priority Data: 61/682,920 14 August 2012 (14.08.2012) US (71) Applicant: NANYANG TECHNOLOGICAL UNIVER­ SITY [SG/SG]; 50 Nanyang Avenue, Singapore 639798 (SG). Inventors: LESCAR, Julien; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). WONG, Yee Hwa; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). CHUA, Wei Min Edmond; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). TAN, Nguan Soon Andrew; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). CHONG, Han Chung Kelvin; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). TAN, Ming Jie; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). HUANG, Roy- ston-Luke; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). [Continued on next page] (54) Title: ANGIOPOIETIN-LIKE 4 ANTIBODY AND A METHOD OF ITS USE IN CANCER TREATMENT goc akc gag ctc ocfc cag tct c 1 2 3 4 S 5 7 0 I E L T Q S l get tct ttg get gtg tct eta ggg <og agg gee occ 9 1® 11 12 13 14 15 l« 17 IS 19 2& ASLAVSLCQRAT (57) Abstract: An antibody that binds C terminal region of angiopoietin like protein its use and methods 4 of treating can­ cer with the same. otc ice tgc esg get age caa ogt gtt gat tot gat ggt got ogt tat ttg aac tgg tfcc 21 22 23 24 25 26 17 2S 2fl 3® 31 32 33 iM SS 56 3? tt 39 4& ISCXASQSVDfDCOSYLtlHF • Li - caa cag aaa c eg gga cag cca ccc ao a ctc ctc ctc tat oct gca tcc act eta gca tct 41 42 43 44 -15 46 4 7 43 49 SB 31 52 S3 54 55 56 S? 58 59 68 4QKPGQPPKILIYTASNLES < 12 §ga ate cca gcc agg tfct ogt ggc: agt ggg tct ggg oca gar, ttc occ etc aac otc est 62 63 (A S5 66 6? 68 69 TO ?1 12 73 74 75 76 77 78 79 fi» CSPARPSGSC. SCTOFTLMIK cCt gtg g<% &Q gag gat get gca acc tat tac tgt oag cos agt oat gag got ccg tg$ SI 82 S3 W SS 84 4? S3 89 S& 91 93 W 95 9® £7 98 99 1M PYEEEOfiATVyCQQSNEDPW 13 ocg tic ggt §ga ggc ate oag ttg gca atfl <aaa egg Ifll 182 103 184 185 106 US? 163 1B9 110 111 112 TF6GGTKLE2KS Heavy chain cag gfcg caa ctg cog gag tct gac cct ggg eta ttg aag ccc tea cag acc ctc agt ctg i 2 3 4 5 6 7 3 9 1» U 12 13 14 15 16 17 18 13 itt QV QlQfSGP&ZlKPSQTLSL <jct tgt tct ttc tct ggg ttt tco ctg age set tct ggt atg ggt gto ggc tgg ott tgt 21 22 23 24 25 26 27 2S 29 3& 31 32 33 34 35 .36 37 38 39 4ft TCSFSCFSLSTSGMGVGHIR Hi > cog cct tea ggg aag ggt ctg gag tgg ctg gca cac att tgg tgg gat got got cog tac 41 42 43 44 45 +6 47 48 49 5& 51 52 S3 S4 55 56 57 58 59 £0 QPS&KCLE ffLAH ItfHODDKy < H2 tat aac cca tcc ctg aag age cag ctc aco ate tee asg 61 62 63 64 6S £6 67 S2 63 ?& 72 72 73 VNPSLKSQiTISS $at acc tcc aga aac cag gto 74 75 76 77 74 ?3 I® £> T S ft H $ V ir. o\ i> rs o ttc ctc aag ate ate ogt gtg gac act gca gat act gcc act toe tac tgt get cga add B1 82 83 34 85 S6 &7 &Z S9 3d il «2 93 54 95 S6 37 9S 93 ICS FLKttSVftTAOTATYVCik'ftK gac tac gge agt ogt tac ©ac toe tgg ggc cca ggg occ acg gtc acc gtc tcc Ifll 102 m M 105 106 107 IdS 169 110 111 112 113 114 115 116 117 118 0*6 SSYfiyWGfiCTTVTyS H3 > O CJ o & WO 2014/027959 A11II llll IIII III III Hill III III III Hill 111 II lllll llll 111 mill llll 111 llll (74) Agent: VIERING, JENTSCHURA & PARTNER LLP; P.O. Box 1088, Rochor Post Office, Rochor Road, Singa­ pore 911833 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201408340SA 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment SG11201408340SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682920P 2012-08-14 2012-08-14
PCT/SG2013/000331 WO2014027959A1 (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Publications (1)

Publication Number Publication Date
SG11201408340SA true SG11201408340SA (en) 2015-01-29

Family

ID=50101350

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408340SA SG11201408340SA (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment
SG10201701165TA SG10201701165TA (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201701165TA SG10201701165TA (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Country Status (5)

Country Link
US (1) US20150210758A1 (en)
EP (1) EP2885319B1 (en)
CN (1) CN104768972B (en)
SG (2) SG11201408340SA (en)
WO (1) WO2014027959A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301313D0 (en) 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
CU24453B1 (en) 2014-08-07 2019-11-04 Novartis Ag ANTI-PROTEIN ANTIBODIES SIMILAR TO ANGIOPOYETIN 4
WO2021221565A1 (en) * 2020-04-27 2021-11-04 Nanyang Technological University HUMANIZED MONOCLONAL ANTIBODY AGAINST cANGPTL4

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
KR20030033007A (en) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
CN101044164A (en) * 2004-07-20 2007-09-26 健泰科生物技术公司 Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2488640B1 (en) * 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
EP2742361A4 (en) * 2011-08-08 2015-03-04 Univ Nanyang Tech Angiopoietin-like 4 and its use in modulating cell leakiness

Also Published As

Publication number Publication date
SG10201701165TA (en) 2017-03-30
WO2014027959A1 (en) 2014-02-20
CN104768972B (en) 2019-12-06
EP2885319B1 (en) 2019-10-09
EP2885319A1 (en) 2015-06-24
EP2885319A4 (en) 2016-06-01
US20150210758A1 (en) 2015-07-30
CN104768972A (en) 2015-07-08

Similar Documents

Publication Publication Date Title
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201803933PA (en) Optical metrology of lithographic processes using asymmetric sub-resolution features to enhance measurement
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201408269PA (en) Nanosilica coating assembly with enhanced durability
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201407028WA (en) St2l antagonists and methods of use
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201408362SA (en) Production of long chain polyunsaturated fatty acids in plant cells
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201408312UA (en) Method of preparing a composition based on hyaluronic acid
SG11201408340SA (en) Angiopoietin-like 4 antibody and a method of its use in cancer treatment
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201901468SA (en) Antibodies with reduced binding to process impurities
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201407817RA (en) Coating a substrate web by atomic layer deposition
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201407650VA (en) Composition and process for stripping photoresist from a surface including titanium nitride
SG11201408103XA (en) Polyurethane-based waterproofing composition for the water-proofing of concrete structures
SG11201806791VA (en) Lubricant for a two-stroke marine engine